Summary tables comparing neoplastic disorders: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
|- | |- | ||
|colspan="1" style = "font-size:80%; width: 20%; |'''Marker''' | |colspan="1" style = "font-size:80%; width: 20%; |'''Marker''' | ||
|colspan="1" style = "font-size:80%; width: | |colspan="1" style = "font-size:80%; width: 15%; |'''CLL''' | ||
|colspan="1" style = "font-size:80%; width: | |colspan="1" style = "font-size:80%; width: 15%; |'''MCL''' | ||
|colspan="1" style = "font-size:80%; width: | |colspan="1" style = "font-size:80%; width: 15%; |'''FL''' | ||
|colspan="1" style = "font-size:80%; width: | |colspan="1" style = "font-size:80%; width: 15%; |'''MZL''' | ||
|colspan="1" style = "font-size:80%; width: | |colspan="1" style = "font-size:80%; width: 15%; |'''HCL''' | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" |'''κ/λ''' | |colspan="1" style = "font-size:90%; color:black;" |'''κ/λ''' |
Revision as of 00:11, 22 June 2023
Immunophenotype LPD | |||||
---|---|---|---|---|---|
Marker | CLL | MCL | FL | MZL | HCL |
κ/λ | 40:80 wk | >80 | 40:80 var | >80 | >80 stg |
FMC7 | 20:40 wk | 40:80 | 40:80 | ||
CD5 | >80 | >80 longer | <5% | ||
CD10 | 5-20 | 5-20 | >80 Stg | ||
CD11C | 20:40 wk | 20:40 wk | <5% | ||
CD19 | >80 | >80 | 40:80 | ||
CD20 | >80 | >80 | >80 | ||
CD23 | >80 | 5-20 | 40:80 | ||
CD25 | 20:40 wk | 20:40 wk | 5-20 wk | ||
CD38 | 20:40 | >80 | >80 | ||
CD43 | >80 | 40:80 | <5% | ||
CD79b | >80 wk | >80 | >80 | ||
CD103 | <5% | <5% | <5% | ||
CD138 | <5% | <5% | <5% | ||
CD200 | >80 | <5% | <5% |
Key to table:
Key to colour code Click for link
Key to expression code Click for link